HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

exemestane (Aromasin)

a hormonal antineoplastic agent
Also Known As:
Aromasin; 6-methyleneandrosta-1,4-diene-3,17-dione; Aromasil; Aromasine; FCE 24304; FCE-24304; examestane
Networked: 910 relevant articles (130 outcomes, 367 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Stearns, Vered: 23 articles (10/2022 - 09/2008)
2. Ingle, James N: 22 articles (01/2022 - 09/2003)
3. Goss, Paul E: 19 articles (10/2021 - 08/2003)
4. van de Velde, Cornelis J H: 19 articles (01/2021 - 01/2011)
5. Pritchard, Kathleen I: 17 articles (01/2018 - 10/2005)
6. Hayes, Daniel F: 16 articles (10/2022 - 09/2008)
7. Henry, N Lynn: 15 articles (10/2022 - 09/2008)
8. Rugo, Hope S: 15 articles (01/2021 - 02/2012)
9. Hortobagyi, Gabriel N: 15 articles (01/2019 - 03/2004)
10. Seynaeve, Caroline: 14 articles (01/2019 - 01/2009)

Related Diseases

1. Breast Neoplasms (Breast Cancer)
2. Neoplasms (Cancer)
3. Disease Progression
4. Colorectal Neoplasms (Colorectal Cancer)
07/01/2015 - "Recent large phase III clinical trials, including the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG-12), Suppression of Ovarian Function Trial (SOFT), and Tamoxifen and Exemestane Trial (TEXT), did not demonstrate an improvement in disease-free survival with ovarian suppression in the overall population. "
08/01/2007 - "Recent data on the NSABP B-33 trial, which investigated exemestane in the extended adjuvant setting, and Austrian Breast and Colorectal Cancer Study Group (ABCSG) trial 6a, which evaluated anastrozole in the extended adjuvant setting, have also been reported. "
01/01/2008 - "A smaller open-label trial, the Austrian Breast and Colorectal Cancer Study Group 6a has reported a significant benefit for anastrozole on recurrence when used as extended adjuvant therapy when compared with no treatment, and similar results have been seen with extended adjuvant exemestane in the National Surgical Adjuvant Breast and Bowel Project B-33 trial. "
11/01/2008 - "Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)."
12/01/2006 - "Three other trial were designed as cross-over studies; the Intergroup Exemestane Study (IES) and the Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 8/German ARNO 95 trial compared a crossover from tamoxifen to an aromatase inhibitor versus continued tamoxifen in women who had completed 2 to 3 years of tamoxifen. "
5. Neoplasm Metastasis (Metastasis)

Related Drugs and Biologics

1. Tamoxifen
2. Aromatase Inhibitors
3. Hormones (Hormone)
4. Anastrozole (Arimidex)
5. Everolimus
6. Letrozole (Femara)
7. Estrogen Receptors
8. Aromatase (CYP19)
9. Fulvestrant (Faslodex)
10. ErbB Receptors (EGF Receptor)

Related Therapies and Procedures

1. Therapeutics
2. Drug Therapy (Chemotherapy)
3. Aftercare (After-Treatment)
4. Chemoprevention
5. Neoadjuvant Therapy